Trials / Recruiting
RecruitingNCT04356664
Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis
Benefit of Gonadotropin-releasing Hormone (GnRH) Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and / or Adenomyosis: Randomized Prospective Study
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Hopital Foch · Academic / Other
- Sex
- Female
- Age
- 18 Years – 36 Years
- Healthy volunteers
- Not accepted
Summary
Women suffering from endometriosis and/or adenomyosis may also suffer from infertility. GnRH agonist injection could improve implantation and therefore increase the pregnancy rate in these patients. This study was designed to evaluate effects of the additional of GnRH agonist (single or 2 doses) to the routine oestrogens and progestins use as support before Frozen Embryon Transfer as compared to oestrogens and progestins only.
Detailed description
Endometriosis reveals the presence of glands or endometrial stroma outside the uterus, responsible for pain and infertility. Adenomyosis illustrates an invagination of endometrial islets within the myometrium, leading to a disturbance of its contractile activity, also potentiated by local hyperestrogenism. These two pathologies are often associated, and express an alteration of the eutopic endometrium by pro-inflammatory markers responsible for a lower implantation rate. GnRH agonists are known to decrease these pro-inflammatory markers (cytochrome P450 and Cox 2 aromatase) in the eutopic endometrium of women with endometriosis or adenomyosis. Patients will received 1 or 2 injection of GnRH delay agonist (Decapeptyl 3mg) approximately 1 month before the frozen embryo transfer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GnRH agonist | One or two intramuscular injections of Decapeptyl 3 mg |
Timeline
- Start date
- 2021-03-18
- Primary completion
- 2026-06-18
- Completion
- 2026-06-18
- First posted
- 2020-04-22
- Last updated
- 2026-01-16
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04356664. Inclusion in this directory is not an endorsement.